

**Which examination is most useful in assessing the phenotype of left ventricular noncompaction cardiomyopathy in children – echocardiography, cardiovascular magnetic resonance, or both?**

*Short title: Comparison of echocardiography and cardiovascular magnetic resonance in pediatric LVNC*

Authors list:

Agata Paszkowska, MD, Department of Cardiology, The Children's Memorial Health Institute, 04-730 Warsaw, Poland

Jędrzej Sarnecki, MD, Department of Diagnostic Imaging, The Children's Memorial Health Institute, 04-730 Warsaw, Poland

Alicja Mirecka-Rola, MD, Department of Cardiology, The Children's Memorial Health Institute, 04-730 Warsaw, Poland

Monika Kowalczyk-Domagala, MD PhD, Department of Cardiology, The Children's Memorial Health Institute, 04-730 Warsaw, Poland

Łukasz Mazurkiewicz, MD PhD, Department of Cardiomyopathies, Cardiovascular Magnetic Resonance Unit, National Institute of Cardiology, 04-682 Warsaw, Poland

Lidia Ziolkowska, Prof. of CMHI, MD PhD, Department of Cardiology, The Children's Memorial Health Institute, 04-730 Warsaw, Poland

Corresponding Author:

Lidia Ziółkowska ✉, Prof. of CMHI, MD PhD, Department of Cardiology, The Children's Memorial Health Institute, Al. Dzieci Polskich 20, 04-730 Warsaw, Poland

Tel. + 48 22 8157370, Fax. +48 228157365, e-mail. l.ziolkowska@ipczd.pl

Orcid ID No: 0000-0003-0300-1941

Authors Agata Paszkowska and Jędrzej Sarnecki were involved equally in this work and both should be considered as a first author.

## Abstract

**Background:** Left ventricular noncompaction (LVNC) is a distinct cardiomyopathy characterized by the presence of a two-layer myocardium with prominent trabeculation and deep intertrabecular recesses. The diagnosis of LVNC can be challenging because the diagnostic criteria are not uniform. The aim of our study was to evaluate echocardiographic and CMR findings in a group of children with isolated LVNC.

**Methods:** From February 2008 to July 2021, pediatric patients under 18 years of age at the time of diagnosis with echocardiographic evidence of isolated LVNC were prospectively enrolled. The patients underwent echocardiography and contrast-enhanced cardiovascular magnetic resonance (CMR) with late gadolinium enhancement to assess myocardial noncompaction, ventricular size, and function.

**Results:** A total of 34 patients with a median age of 11.9 years were recruited. Patients were followed prospectively for a median of 5.1 years. Of the 31 patients who met Jenni's criteria in echocardiography, CMR was performed in 27 (79%). Further comprehensive analysis was performed in the group of 25 patients who met the echocardiographic and CMR criteria for LVNC. In echocardiography, the median NC/C ratio in systole was 2.60 and in diastole 3.40. In 25 out of 27 children (93%), LVNC was confirmed by CMR according to Petersen's criteria, with a median NC/C ratio of 3.27.

**Conclusions:** 1) Echocardiography precisely identifies patients with LVNC. 2) Echocardiography is a good method for monitoring LV systolic function, but CMR is indicated for the precise assessment of LV remodeling and RV size and function as well as for the detection of myocardial fibrosis.

**Keywords:** left ventricular noncompaction, cardiomyopathy, imaging, echocardiography, cardiovascular magnetic resonance, children

## INTRODUCTION

Left ventricular noncompaction (LVNC) is described as a distinct cardiomyopathy characterized by a two-layer myocardium with prominent trabeculation, deep intertrabecular recesses, and a thin compacted myocardial layer. LVNC was classified as a primary cardiomyopathy by the American Heart Association in 2006 [1], but remains unclassified by the European Society of Cardiology [2]. It typically involves the left ventricle, although involvement of the right ventricle (RV) has been reported [3]. LVNC can occur as an isolated or non-isolated phenotype. Non-isolated LVNC may be accompanied by congenital heart diseases or features of other cardiomyopathy or neuromuscular diseases. LVNC is a genetically determined myocardial disease, the third most common cardiomyopathy in the pediatric population (after dilated and hypertrophic cardiomyopathy). Molecular studies have confirmed the genetic etiology in approximately 40% of LVNC patients [4,5]. The clinical presentation is very heterogeneous, ranging from no symptoms to major events such as heart failure, arrhythmias, thromboembolism, and sudden cardiac death [6,7,8].

The diagnosis of LVNC can be challenging due to the non-uniform diagnostic criteria. Echocardiography is the initial and basic tool for diagnosing this cardiomyopathy according to the morphological criteria [9,10]. So far, no separate morphological criteria for LVNC in children have been proposed. The most commonly used echocardiographic criteria are those provided by Jenni et al. [11].

In recent years, cardiovascular magnetic resonance (CMR) imaging has increasingly been used in the assessment of cardiomyopathies. It is currently considered the non-invasive gold standard for the evaluation of biventricular volumes, myocardial mass, regional and global systolic function, and tissue characteristics [12]. CMR may provide clinically relevant information and it allows for LVNC diagnosis, though the proposed diagnostic criteria vary. Because these criteria are based on small samples of patients and various assumptions and

because there is no accepted standard for children, their reliability remains undetermined for the pediatric population [13]. For CMR, Petersen's criteria are most frequently used in clinical practice [14]. The emergence of CMR has enabled high-resolution imaging of cardiac structures, which provides detailed functional and morphologic information and allows for the presence and extent of fibrosis to be assessed [15]. Literature reports indicate that CMR is superior to echocardiography in assessing the extent of myocardial noncompaction, especially in areas which are not accessible by echocardiography, such as the left ventricular apex and the lateral wall [16].

The aim of our study was to evaluate echocardiographic and CMR findings in a group of children with isolated LVNC.

## **MATERIAL AND METHODS**

### **Study patients**

From February 2008 to July 2021, pediatric patients with echocardiographic features of LVNC who were hospitalized in the Department of Cardiology of the Children's Memorial Health Institute were prospectively enrolled. The criteria for inclusion in the study were an age of less than 18 years at the time of diagnosis and echocardiographic evidence of isolated LVNC, defined as 1) the presence of a two-layer structure with a compacted and noncompacted endocardial layer of trabecular meshwork with deep endomyocardial spaces, 2) a maximal end-systolic ratio between the noncompacted and compacted (NC/C) layers of 2.0 or greater, and 3) color Doppler evidence of deep perfused intertrabecular recesses. The Institutional Ethics Committee approved this study. Informed consent was obtained from all individual participants included in the study.

## **Data collection**

Patients' demographics, family history of cardiomyopathies and sudden cardiac death (SCD), and results from echocardiography, 12-lead resting ECG, 24-hour Holter ECG, and CMR were collected. NYHA/Ross functional class and clinical symptoms – such as chest pain, palpitations, syncope, pre-syncope, and thromboembolic events – were evaluated in all children.

## **Echocardiographic imaging and analysis**

Echocardiographic imaging was performed using a Philips Epiq7 (Philips Medical Systems, Bothell, WA). Two-dimensional, Doppler, and M-mode echocardiography were performed at rest using standard methods. Echocardiographic images, including parasternal long- and short-axis and apical two-, three-, and four-chamber views were obtained and reviewed by cardiologists certified in echocardiography.

Echocardiographic measurements were reviewed based on Jenni's criteria [11]: a ratio of LV NC to C myocardial layer of 2.0 or greater, measured in the parasternal short-axis view in end-systolic phase below the papillary muscle. The NC/C ratio was additionally calculated in the parasternal short-axis projection in end-diastolic phase. Color Doppler imaging was performed in all children with visualization of the recess filling between the trabeculae with blood flowing in from the left ventricle (LV). LV dimension and systolic function were evaluated in detail. Echocardiographic measurements included LV end-diastolic (LVED) and end-systolic (LVES) volume [17] and area [18] in the apical four-chamber view, as well as LV diastolic (LVDd) and systolic (LVSD) diameters in the parasternal long-axis projection [19]. These parameters were evaluated for each patient and indexed to the patient's BSA according to Du Bois' formula. Moreover, z-scores were calculated using the formula for z-scores reported in the literature [20]. LV systolic function was assessed by calculating the shortening fraction (SF), ejection fraction (LVEF) – according to Simpson's method – the

value of mitral annulus peak systolic excursion (MAPSE) in mm, and z-score [21]. LA dimension (LAd) was measured at end-systole as the anteroposterior linear diameter from the parasternal long-axis view and was indexed to the patient's BSA. The z-score for LAd was calculated with the formula for z-scores [17]. LA enlargement was defined as a z-score greater than 2. It should be pointed out that the echocardiographic study also assessed the RV dimension and systolic function. RV diastolic diameter (RVDd) was evaluated in the parasternal long-axis view (mm, z-score) [17]. RV systolic function was assessed by calculating tricuspid annular plane systolic excursion values in mm and the z-score [22] and by measuring the fractional area change as a percentage of the difference between the RV end-diastolic and end-systolic areas evaluated in the apical four-chamber view.

### **CMR imaging and analysis**

CMR imaging was performed using a 1.5-T scanner (Magnetom AvantoFit, Siemens, Erlangen, Germany), with a dedicated cardiac phased-array coil and electrocardiographic (ECG) gating. Steady-state free precession (SSFP) cine images of the heart were acquired in the short-axis and four-, three-, and two-chamber planes with a minimum of 25 phases per cardiac cycle. Late gadolinium-enhanced (LGE) images were acquired in the short-axis and long-axis planes 10–15 min after intravenous administration of 0.1 mmol/kg of gadobutrol (Gadovist, Bayer, Berlin, Germany).

The studies were analyzed using CVI42 software (Circle Cardiovascular Imaging, Calgary, Canada) on a dedicated diagnostic workstation. Cine images were used to determine the left and right ventricular volumes, ejection fraction, and left ventricular mass (LVM). The end-diastolic and end-systolic phases were identified based on long-axis and midventricular short-axis scans. The LV endocardial and epicardial borders and the RV endocardial border were automatically contoured in those phases and then manually corrected to determine the end-diastolic (EDV) and end-systolic (ESV) volumes of both ventricles. Based on the results, the

LV and RV stroke volumes ( $SV = EDV - ESV$ ) and ejection fraction ( $EF = SV/EDV \times 100\%$ ) were calculated. Compacted LVM, including the interventricular septum and the LV papillary muscles, was calculated based on segmentation in the end-diastolic phase. LV global mass was determined by manually drawing the LV endocardial border to include both papillary muscles and LV trabeculation. The LV noncompacted mass was then established by subtracting the compacted LVM from the global LVM. The LV thickness of the compacted and the noncompacted myocardial layers was measured in end-diastole (excluding the 17th segment, according to the American Heart Association model); the highest NC/C ratio value was recorded.

LV and RV compacted mass, EDV, ESV, SV, and LV trabeculation mass were indexed to the patient's BSA, determined using Du Bois' formula ( $BSA [m^2] = 0.007184 \times \text{weight [kg]}^{0.425} \times \text{height [cm]}^{0.725}$ ). To identify morphological abnormalities, LVM, LV EDV, and RV EDV were compared against recently published, multicenter CMR normative values for children and adolescents, which were determined using the same methods [23]. Z-score values of less than  $-2.0$  and greater than  $2.0$  were considered pathological.

The studies were visually assessed for the presence of myocardial LGE, which had to be present in two different spatial orientations. Additionally, the extent of LGE was quantitatively assessed using a dedicated module within CVI42, where pathological enhancement was defined as a myocardium with a signal intensity more than 6 SD above the mean in a remote reference region of effectively nulled myocardium.

### **Statistical analysis**

The distribution of all continuous variables was assessed using the Shapiro–Wilk test. Normally distributed variables are presented as mean  $\pm$  SD, whereas non-normally distributed parameters are given as median (interquartile range). Echocardiographic diagnostic



performance was assessed in relation to CMR using standard accuracy criteria for binary diagnostic tests (i.e., sensitivity, specificity, and accuracy) with Clopper–Pearson confidence intervals and positive and negative predictive values with confidence intervals calculated according to Mercado et al.[24]. Pearson’s correlation coefficient and the Bland–Altman plot were used to compare LV EDV between the imaging methods. Participants with myocardial LGE detected in CMR were compared with the children without myocardial LGE using an unpaired *t*-test or Mann–Whitney test, depending on the normality of the distribution. Categorical variables between groups were compared using the chi-squared test. *P*-values less than 0.05 were considered statistically significant. Statistical analysis was carried out using MedCalc Statistical Software 20.014 (MedCalc Software Ltd, Belgium).

## RESULTS

### Clinical characteristics

A total of 34 patients with an echocardiographic diagnosis of LVNC were recruited between February 2008 and July 2021. The median age was 11.9 years (6.6–14.7) and 50% were male. The patients were followed prospectively for a median of 5.1 years (2.2–12.2).

In the study group, 3% of patients were under 1 year of age; 32% were between 1 and 10 years of age; and 65% were over 10 years of age. Family history revealed cardiomyopathy in first-degree relatives in 11 children (32%) (LVNC in 20% of patients; both LVNC and DCM in 6%; LVNC and HCM in 3%; and HCM in 3%). Sudden cardiac deaths occurred in the families of 3 children (9%). The NYHA/Ross functional class in the majority of patients (74%) was evaluated as grade II; 3% had grade IV, while 24% had grade I. In 24-hour ECG Holter monitoring, the most prominent features were premature ventricular and atrial contractions, found in 26% and 15% of patients, respectively. Other findings were observed,

including sinus bradycardia in 21% of children, paroxysmal third-degree atrioventricular block in 12%, ventricular tachycardia in 9%, and Wolff–Parkinson–White syndrome in 6% of patients.

**Echocardiographic results**

In 31 of the 34 patients (91%), the median NC/C ratio was 2.60 (IQR, 2.22,3.40). In the remaining 3 patients (9%) referred from a regional center with a diagnosis of LVNC, the echocardiography performed in our cardiology center did not confirm the diagnosis, as the NC/C ratios ranged from 1.46 to 1.9. These patients were excluded from further analysis and were not referred for CMR examination.

CMR was performed in 27 of the 31 children (79%) who met Jenni’s criteria in echocardiography. In 4 (13%) patients, CMR was not performed due to their severe clinical condition and the implantation of an LV assist device for mechanical circulatory support ( $n = 1$ ), an implanted pacemaker ( $n = 2$ ), and hemodynamic instability and low body weight ( $n = 1$ ). Among the 27 children who underwent CMR, the diagnosis of LVNC was confirmed in 25 (93%) according to Petersen’s criteria. In 2 patients (7%), the CMR investigations did not confirm echocardiographic diagnosis of LVNC, as the NC/C ratio was less than 2.3.

A comprehensive and detailed analysis was performed on a group of 25 patients who met the echocardiographic and CMR criteria for LVNC diagnosis. The baseline characteristics of the study group are presented in Table 1.

.....Table 1.....

In the group of 25 patients, the median NC/C ratio in systole was 2.60 (IQR, 2.22,3.30) and in diastole 3.40 (IQR, 2.77,4.80). In echocardiography, LVDd was increased in 10 patients (40%) (LVDd, 42–59.5 mm; z-score, +2.5 to +4.6). Of these, 4 patients (16%) had LV systolic function impairment (LVEF, 50%–55%; MAPSE, 9.6–16.5 mm; z-score, -2.8 to

+1.6); in the remaining 6 children, LVEF was normal. In 2 children, a reduction of LVEF was observed without an increase in LVDd.

In 1 patient (4%), apart from LV enlargement and a reduction of LVEF, an impairment of RV systolic function was found (fractional area change, 30%; tricuspid annular plane systolic excursion, 18.5 mm; z-score, -1.5) with RV normal size. On the other hand, in 1 patient (4%), RV enlargement (36 mm; z-score, +2.8) with normal systolic function was observed. LA enlargement was found in 2 patients (8%) (LAd, 35 mm; z-score, from +3.4 to +4). Table 2 presents the results of echocardiographic and CMR imaging from 25 patients with LVNC.

.....Table 2.....

**CMR results**

Twenty-seven participants meeting the echocardiographic criteria of LVNC underwent CMR with LGE assessment. In 25 out of 27 children (93%), LVNC was confirmed by CMR according to Petersen’s criteria, with a median NC/C ratio of 3.27 (IQR, 2.56,3.76). LV enlargement was diagnosed in 5 out of 25 children (20%) with LVNC, LV function impairment was diagnosed in 6 of the 25 (24%), RV enlargement in 4 (16%), RV function impairment in 7 (28%), and LA enlargement in 5 (20%) (Table 2). RV EF was strongly correlated with LV EF ( $r=0.76$ ;  $p<0.001$ ) (Figure 1), though it was not associated with LV or RV volumes.

.....Figure 1.....

In 6 out of the 25 patients (24%), midwall LGE was observed involving on average  $6.6\pm2.4\%$  of the LV myocardial mass. Compared to the children with LVNC without LGE, they had larger LV, characterized by higher LV EDV/BSA ( $101\pm34$  vs.  $78\pm13$  ml/m<sup>2</sup>,  $p=0.02$ ) (Figure 2) as measured by CMR and higher LV EDV index as measured in echocardiography ( $61\pm13$  vs.  $77\pm19$  ml/m<sup>2</sup>;  $p=0.032$ ). They also had higher LV SV/BSA ( $62\pm21$  vs.  $49\pm9$  ml/m<sup>2</sup>;  $p=0.026$ ), RV SV/BSA ( $63\pm22$  vs.  $48\pm9$  ml/m<sup>2</sup>;  $p=0.022$ ), and LV compacted

mass/BSA (63 [48, 70] vs. 48 [44, 53] g/m<sup>2</sup>;  $p=0.043$ ). The groups of LVNC patients with and without LGE did not differ in other parameters assessed in CMR or echocardiography, including LV NC/C ratio, LVEF, RVEF, RV EDV/BSA, or LA maximum volume.

.....Figure 2.....

**Comparison of echocardiographic and CMR results**

In the CMR investigations, LV NC/C ratio significantly correlated with echocardiographic NC/C ratio measured in systole ( $r=0.41$ ;  $p=0.044$ ) , but not in diastole (Table 3).

.....Table 3.....

There were no significant correlations between LV NC/C and LV volumes or function. When referenced to CMR, which is the gold standard for ventricular size and function assessment, echocardiographic examination had high accuracy for detecting LV function impairment (92% [74%–99%]), with high specificity (95% [74%–100%]) and moderate sensitivity in children with LVNC (Table 4).

.....Table 4.....

However, the LVEF values measured using the two imaging methods were not significantly correlated ( $r=0.36$ ;  $p=0.08$ ). The mean difference between the echocardiographic and CMR results was  $-2.4\%\pm7.8\%$  and the lower and upper limits of agreement (LoA) were  $-18.1\%$  and  $13.3\%$ .

Echocardiography had moderate sensitivity for diagnosing LV enlargement (80% [28%–99%]), but its specificity and overall accuracy in this aspect were relatively low (65% [41%–85%]) and 68% [47%–85%], respectively). Nevertheless, the results acquired with these methods were very strongly correlated ( $r=0.93$ ;  $p<0.0001$ ). The mean difference between the echocardiographic and CMR LV EDV results was  $-25.9$  ml (lower and upper LoA,  $-67$  ml

and 15.2 ml, respectively); the mean difference between LV EDV/BSA measurements was  $-18.6 \text{ ml/m}^2$  (lower and upper LoA,  $-45.5 \text{ ml/m}^2$  and  $8.3 \text{ ml/m}^2$ , respectively) (Figure 3).

.....Figure 3.....

For both absolute and indexed LV EDV, the differences increased with higher values (regression coefficients,  $-0.29$ ;  $p=0.001$  and  $-0.35$ ;  $p = 0.02$ , respectively).

Echocardiography had high specificity for detecting RV function impairment (100% [81%–100%]) and enlargement (95% [76%–100%]); however, its sensitivity in the assessment of those abnormalities was very low (14% [0%–58%] and 25% [1%–81%], respectively). Similarly, echocardiography had very high specificity in LA enlargement diagnosis (100% [83%–100%]), but its sensitivity in this aspect was relatively low (40% [5%–85%]), as presented in Table 4.

**DISCUSSION**

The main findings of this prospective observational study on LVNC in children are as follows:

1. Echocardiography is a precise method for diagnosing LVNC and it can accurately identify LV function impairment.
2. Almost one fourth of pediatric patients with LVNC present with features of myocardial fibrosis.
3. Right ventricular abnormalities, which are often present in children with LVNC, can only be reliably assessed with CMR.

Among the cardiac imaging techniques used in patients with LVNC, echocardiography and CMR are the primary diagnostic methods. The advantages of echocardiography over CMR are that it is more available, the costs of examination are lower, and there is no need for

anesthesia in younger children. Consequently, echocardiography is the first choice in the diagnosis of LVNC [25]. Echocardiography, however, has its limitations. First of all, there is a wide range of echocardiographic diagnostic criteria in the literature, based on studies with small samples using different research methodologies [9,17]. The cardiac cycle (end-systole or end-diastole) in which the measurements of the noncompacted and compacted layers are made is also important, as the thickness of the myocardium is maximal in systole and minimal in diastole, which directly affects the NC/C ratio. The next point of discussion is the echocardiographic projection in which the measurements for the NC/C ratio should be made. Most of the published diagnostic criteria suggest that these measurements should be performed in the LV parasternal short-axis view; however, the apical four- and two-chamber views are most commonly used in everyday clinical practice. Finally, there is no uniform consensus on the threshold value of NC/C ratio to use as a diagnostic criterion for LVNC [17]. The most frequently used criteria are those presented by Jenni et al., which are dedicated to adult patients; the suggested NC/C ratio is 2:1 or higher [11]. These echocardiographic criteria were used in our study, as in other published studies on children with LVNC [26], although some authors have proposed an NC/C ratio of greater than 1.4 as diagnostic criterion for LVNC in the pediatric population [27].

Improvements in cardiac imaging modalities, such as echocardiography and CMR imaging, have increased the identification of LVNC [28]. CMR is superior to echocardiography methodologies with regard to the number of segments that can be analyzed and the evaluation of the extent of two-layered myocardia. Moreover, CMR imaging has the potential to detect segmental non-compaction in any area of the LV wall and can provide supplemental morphological information beyond that obtained from conventional echocardiography [29]. Only a few previous studies have compared NC/C ratios assessed by CMR versus echocardiography [29,30]. The advantage of our study is that for the first time it compares

data obtained with CMR and standard echocardiography in a larger group of pediatric patients. The results of our study demonstrate that in as many as 93% of children with LVNC features on echocardiography, CMR confirmed the diagnosis of the disease, which indicates that echocardiography is a precise diagnostic method for LVNC assessment in children.

Some authors have emphasized the role of better visualization of the noncompacted layer of the myocardium and trabeculae in end-diastole in echocardiography [31], while others have shown that end-systolic measurements of LVNC in CMR have stronger associations with cardiac events [32]. In our pediatric study, echocardiography images obtained at end-systole and end-diastole were compared with those obtained by CMR at end-diastole to assess NC/C ratio. Only systolic – not diastolic – NC/C ratios measured in echocardiography significantly correlated with NC/C ratio measurements in CMR, which is different from the results of a study on adult patients that reported good agreement between echocardiography at end-diastole and CMR measurements [29]. The results of our study suggest a strong advantage of evaluating the noncompacted myocardium during systole in echocardiographic studies.

Other authors [33,34] have assessed the correlation between NC/C ratio and LVEF. The results of these studies revealed that patients with increasing severity of noncompaction in echocardiography had significantly lower LVEF and LVEF correlated with parameters of specific diagnostic criteria for LVNC in CMR, such as an NC/C ratio greater than 2.3 and a more than 20% proportion of the noncompacted myocardium being LV mass. We did not find such a correlation in our study group. Nevertheless, 24% of the participants with LVNC confirmed by CMR presented with LV systolic function impairment, which is an important finding, as decreased LVEF is a significant risk factor [35]. Moreover, we observed a high accuracy of echocardiography in diagnosing LV systolic function impairment when referenced to the CMR, indicating its utility in patient follow-up. LV enlargement was observed in CMR in 5 of the 25 participants with LVNC (20%), indicating a significant

incidence of LV remodeling in children with LVNC. Admittedly, echocardiography had moderate sensitivity for diagnosing LV enlargement (80%), though its specificity and overall accuracy in this aspect was relatively low.

Contrast-enhanced CMR with LGE imaging may detect myocardial fibrosis [36]. It is relatively frequently observed in patients with LVNC, though its presence or absence is not a reliable diagnostic marker of the disease [37]. In a study by Grothoff et al.[38], none of the LVNC patients demonstrated LGE, while other authors have described the presence of LGE in isolated LVNC, which is associated with a poorer LV systolic function [39,40]. In our study, we found LGE in pediatric patients with isolated LVNC and confirmed a relationship between LGE and features of LV remodeling. As in the case of other authors [41], in our study group the presence of LGE was associated with higher values of LVEDV. In contrast, LVEF did not differ between LVNC patients with LGE and other children with LVNC, similar to a study by Andreini et al. [31]. As the presence of LGE in adult LVNC patients was shown to be a significant risk factor [35] of cardiovascular events, our findings of significant incidence of myocardial fibrosis in children with LVNC and associated LV remodeling indicate the clinical importance of CMR imaging in routine evaluation of those patients [31], **Error! Bookmark not defined.** as in children with hypertrophic cardiomyopathy [42].

The results of studies published in the literature [27] indicate a significant share of RV systolic dysfunction in patients with isolated LVNC. There are reports [43] that have emphasized the relationship between RV systolic dysfunction and significantly lower LVEF and relevant LV enlargement. According to the authors [27], patients with impaired RV systolic function have a greater LV volume, lower LV systolic function, and more pronounced myocardial fibrosis, which may indicate that RV dysfunction is a marker of a more advanced stage of LVNC. The results of our study showed a significant correlation between left and right ventricular function, but we did not prove a relationship between RVEF and the size of



the right and left ventricles. The significant incidence of RV enlargement and RV systolic function impairment observed in children with LVNC further highlights the clinical significance of CMR imaging in this population, since the possibilities of echocardiography RV evaluation are limited.

Based on our experience, we can summarize that echocardiography should be used as the first diagnostic test in LVNC, while CMR is strongly recommended as a complementary examination to accurately assess the extent of myocardial noncompaction and to reliably analyze the size and systolic function of the ventricles.

The results of studies on LVNC in children published so far require further research due to the many unanswered questions regarding diagnostic methods, diagnosis, and clinical management.

## CONCLUSIONS

1. In the morphological assessment of myocardial noncompaction among the study group of pediatric patients, there was very good agreement between echocardiography and CMR imaging.
2. A significant correlation was demonstrated in the assessment of NC/C ratio from end-systole measurements in echocardiography and in end-diastole measurements in CMR examination.
3. Echocardiography is a good method for monitoring LV systolic function, but CMR is indicated for precisely assessing the left ventricle and its enlargement.
4. CMR significantly exceeds echocardiography in the assessment of the right ventricle in children with LVNC and should be included in the basic diagnostics of these patients.

5. CMR imaging allows for the detection of areas of LGE, which are indicative of myocardial fibrosis.
6. LGE incidence is relatively high in pediatric patients with LVNC and is associated with LV remodeling. As it is also a risk factor of future cardiovascular events, contrast-enhanced CMR should be a part of a standard diagnostic work-up of pediatric patients with LVNC.

#### **Author Contributions:**

Conceptualization: LZ, AP, JS; Methodology: LZ, JS, AP, AMR, MKD, ŁM; Validation: LZ, JS, AMR; Formal Analysis: AP, JS, LZ; Investigation: AP, LZ, AMR, JS, MKD, ŁM; Resources: LZ, AP, JS, ŁM; Data Curation, AP, LZ, AMR, MKD, JS; Writing – Original Draft Preparation- AP, JS, LZ, AMR, ŁM; Writing – Review & Editing, LZ, AP, JS; Supervision- LZ. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was founded by The Children's Memorial Health Institute (statutory grant no. S177/2018).

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Ethics Committee of The Children's Memorial Health Institute (protocol code 45/KBE/2018 and date of approval 24/Oct/2018).

**Informed Consent Statement:** Informed consent was obtained from all subjects and their parents involved in the study.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

## REFERENCES

1. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB; American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. *Circulation*. 2006;113(14):1807-16.
2. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kühl U, Maisch B, McKenna W, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. *Eur Heart J*. 2008; 29(2): 270-276.
3. Towbin JA, Lipshultz SE. Genetics of neonatal cardiomyopathy. *Curr Opin Cardiol*. 1999; 14: 250–262.

4. Dong X, Fan P, Tian T, et al. Recent advancements in the molecular genetics of left ventricular noncompaction cardiomyopathy. *Clinica Chimica Acta*. 2017; 465: 40-44.
5. Arbustini E, Favalli V, Narula N, Serio A, Grasso M. Left ventricular noncompaction: a distinct genetic cardiomyopathy? *J Am Coll Cardiol*. 2016; 68(9): 949-66.
6. Engberding R, Stöllberger C, Ong P, Yelbuz TM, Gerecke BJ, Breithardt G. Isolated non-compaction cardiomyopathy. *Dtsch Arztebl Int*. 2010;107(12): 206-13.
7. Liu Y, Chen H, Shou W. Potential Common Pathogenic Pathways for the Left Ventricular Noncompaction Cardiomyopathy (LVNC). *Pediatr Cardiol*. 2018; 39(6):1099-1106.
8. Neudorf U.E, Hussein A, Trowitzsch E, Schmaltz A.A. Clinical features of isolated noncompaction of the myocardium in children. *Cardiol. Young*. 2001; 11: 439–442.
9. Gerecke BJ, Engberding R. Noncompaction Cardiomyopathy-History and Current Knowledge for Clinical Practice. *J Clin Med*. 2021;10(11): 2457.
10. Khosroshahi AG, Zanjani KS, Kocharian A, Zeinaloo A, Kiani A, Rad EM. A novel method for quantification of left ventricular noncompaction using two-dimensional echocardiography in children. *Iran J Pediatr*. 2013; 23(5): 519-24.
11. Jenni R, Oechslin E, Schneider J, Attenhofer Jost C, Kaufmann PA. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. *Heart*. 2001; 86(6): 666-71.
12. Leiner T, Bogaert J, Friedrich MG, Mohiaddin R, Muthurangu V, Myerson S, Powell AJ, Raman SV, Pennell DJ. SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance. *J Cardiovasc Magn Reson*. 2020;22(1):76.

13. Masso AH, Uribe C, Willerson JT, Cheong BY, Davis BR. Left Ventricular Noncompaction Detected by Cardiac Magnetic Resonance Screening: A Reexamination of Diagnostic Criteria. *Tex Heart Inst J*. 2020;47(3):183-193.
14. Petersen S.E, Selvanayagam J.B, Wiesmann F, Robson M.D, Francis J.M, Anderson R.H, Watkins H, Neubauer S. Left ventricular non-compaction: Insights from cardiovascular magnetic resonance imaging. *J Am Coll Cardiol*. 2005; 46: 101–105.
15. Schiau C, Schiau Ș, Dudea SM, Manole S. Cardiovascular magnetic resonance: contribution to the exploration of cardiomyopathies. *Med Pharm Rep*. 2019;92(4):326-336.
16. Choi Y, Kim SM, Lee SC, Chang SA, Jang SY, Choe YH. Quantification of left ventricular trabeculae using cardiovascular magnetic resonance for the diagnosis of left ventricular non-compaction: evaluation of trabecular volume and refined semi-quantitative criteria. *J Cardiovasc Magn Reson*. 2016;18(1):24.
17. Cantinotti M, Scalese M, Giordano R, Franchi E, Marchese P, Vicava C, Assanta N, Iervasi G, Kutty S, Koestenberger M. Pediatric nomograms for left ventricle biplane 2D volumes in healthy Caucasian children. *Echocardiography*. 2020; 37(6):971-975.
18. Cantinotti M, Scalese M, Murzi B, Assanta N, Spadoni I, De Lucia V, Crocetti M, Cresti A, Gallotta M, Marotta M, Tyack K, Molinaro S, Iervasi G. Echocardiographic nomograms for chamber diameters and areas in Caucasian children. *J Am Soc Echocardiogr*. 2014; 27(12):1279-92.
19. Kampmann C, Wiethoff CM, Wenzel A, Stolz G, Betancor M, Wippermann CF, Huth RG, Habermehl P, Knuf M, Emschermann T, Stopfkuchen H. Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe. *Heart*. 2000; 83(6):667-72.

20. Chubb H, Simpson JM. The use Z-score in paediatric cardiology. *Ann Pediatr Cardiol.* 2012; 5(2):179–184.
21. Koestenberger M, Nagel B, Ravekes W, Avian A, Heinzl B, Fritsch P, Fandl A, Rehak, T, Gamillscheg A. Left ventricular long-axis function: Reference values of the mitral annular plane systolic excursion in 558 healthy children and calculation of z-score values. *Am Heart J.* 2012; 164: 125-31.
22. Koestenberger M, Ravekes W, Everett AD, Stueger HP, Heinzl B, Gamillscheg A, Cvirn G, Boysen A, Fandl A, Nagel B. Right ventricular function in infants, children and adolescents: reference values of the tricuspid annular plane systolic excursion (TAPSE) in 640 healthy patients and calculation of z score values. *J Am Soc Echocardiogr.* 2009; 22(6):715-9.
23. van der Ven JPG, Sadighy Z, Valsangiacomo Buechel ER, Sarikouch S, Robbers-Visser D, Kellenberger CJ, Kaiser T, Beerbaum P, Boersma E, Helbing WA. Multicentre reference values for cardiac magnetic resonance imaging derived ventricular size and function for children aged 0-18 years. *Eur Heart J Cardiovasc Imaging.* 2020; 21(1):102-113.
24. Mercaldo ND, Lau KF, Zhou XH. Confidence intervals for predictive values with an emphasis to case-control studies. *Stat Med.* 2007;26(10):2170-83.
25. Hotta VT, Tendolo SC, Rodrigues ACT, Fernandes F, Nastari L, Mady C. Limitations in the Diagnosis of Noncompaction Cardiomyopathy by Echocardiography. *Arq Bras Cardiol.* 2017;109(5):483-488.
26. Ergul Y, Kemal Nisli K Demirel A, Varkal M.A , Oner N , Dursun M , Aygun D, Aydogan U , Omeroglu R.E. Left ventricular non-compaction in children and adolescents: Clinical features, treatment and follow-up. *Cardiology Journal* 2011; 18 (2): 176–184.

27. Pignatelli RH, McMahon CJ, Dreyer WJ, Denfield SW, Price J, Belmont JW, Craigen WJ, Wu J, El Said H, Bezold LI, Clunie S, Fernbach S, Bowles NE, Towbin JA. Clinical characterization of left ventricular noncompaction in children: a relatively common form of cardiomyopathy. *Circulation*. 2003;108(21):2672-8.
28. Wengrofsky P, Armenia C, Oleszak F, Kupferstein E, Rednam C, Mitre CA, McFarlane SI. Left Ventricular Trabeculation and Noncompaction Cardiomyopathy: A Review. *EC Clin Exp Anat*. 2019;2(6):267-283.
29. Thuny F, Jacquier A, Jop B, Giorgi R, Gaubert JY, Bartoli JM, Moulin G, Habib G. Assessment of left ventricular non-compaction in adults: side-by-side comparison of cardiac magnetic resonance imaging with echocardiography. *Arch Cardiovasc Dis*. 2010;103(3):150-159.
30. Alhabshan F, Smallhorn JF, Golding F, Musewe N, Freedom RM, Yoo SJ. Extent of myocardial non-compaction: comparison between MRI and echocardiographic evaluation. *Pediatr Radiol*. 2005;35(11):1147-51.
31. Stöllberger C, Gerecke B, Finsterer J, Engberding R. Refinement of echocardiographic criteria for left ventricular noncompaction. *Int J Cardiol*. 2013;165(3):463-7.
32. Stacey RB, Andersen MM, St Clair M, Hundley WG, Thohan V. Comparison of systolic and diastolic criteria for isolated LV noncompaction in CMR. *JACC Cardiovasc Imaging*. 2013;6(9):931-40.
33. Boban M, Pesa V, Beck N, Manola S, Zulj M, Rotim A, Vcev A. Supplementary Diagnostic Landmarks of Left Ventricular Non-Compaction on Magnetic Resonance Imaging. *Yonsei Med J*. 2018;59(1):63-71.
34. Belanger AR, Miller MA, Donthireddi UR, Najovits AJ, Goldman ME. New classification scheme of left ventricular noncompaction and correlation with ventricular performance. *Am J Cardiol*. 2008;102(1):92-6.


35. Grigoratos C, Barison A, Ivanov A, Andreini D, Amzulescu MS, Mazurkiewicz L, De Luca A, Grzybowski J, Masci PG, Marczak M, Heitner JF, Schwitter J, Gerber BL, Emdin M, Aquaro GD. Meta-Analysis of the Prognostic Role of Late Gadolinium Enhancement and Global Systolic Impairment in Left Ventricular Noncompaction. *JACC Cardiovasc Imaging*. 2019;12(11 Pt 1): 2141-2151.
36. Nucifora G, Aquaro GD, Masci PG, Pingitore A, Lombardi M. Magnetic resonance assessment of prevalence and correlates of right ventricular abnormalities in isolated left ventricular noncompaction. *Am J Cardiol*. 2014;113(1):142-146.
37. Boban M, Pesa V, Gabric ID, Manola S, Persic V, Antic-Kauzlaric H, Zulj M, Vcev A. Auxiliary diagnostic potential of ventricle geometry and late gadolinium enhancement in left ventricular non-compaction; non-randomized case control study. *BMC Cardiovasc Disord*. 2017;17(1): 286
38. Grothoff M, Pachowsky M, Hoffmann J, Posch M, Klaassen S, Lehmkuhl L, Gutberlet M. Value of cardiovascular MR in diagnosing left ventricular non-compaction cardiomyopathy and in discriminating between other cardiomyopathies. *Eur Radiol*. 2012;22(12):2699-709.
39. Nucifora G, Aquaro GD, Pingitore A, Masci PG, Lombardi M. Myocardial fibrosis in isolated left ventricular non-compaction and its relation to disease severity. *Eur J Heart Fail*. 2011 ;13(2):170-176.
40. Zhang J, Jiang M, Zheng C, Liu H, Guo Y, Xie X, Zou Z, Zhou X, Xia L, Luo M, Zeng M. Evaluation of isolated left ventricular noncompaction using cardiac magnetic resonance tissue tracking in global, regional and layer-specific strains. *Sci Rep*. 2021;11(1):7183.
41. Andreini D, Pontone G, Bogaert J, Roghi A, Barison A, Schwitter J, Mushtaq S, Vovas G, Sormani P, Aquaro GD, Monney P, Segurini C, Guglielmo M, Conte E,




- Fusini L, Dello Russo A, Lombardi M, Gripari P, Baggiano A, Fiorentini C, Lombardi F, Bartorelli AL, Pepi M, Masci PG. Long-Term Prognostic Value of Cardiac Magnetic Resonance in Left Ventricle Noncompaction: A Prospective Multicenter Study. *J Am Coll Cardiol*. 2016 15;68(20): 2166-2181.
42. Petryka-Mazurkiewicz J, Ziolkowska L, Kowalczyk-Domagala M, Mazurkiewicz L, Boruc A, Spiewak M, Misko J, Bieganska K, Marczak M, Brzezinska-Rajszyz G. LGE for Risk Stratification in Primary Prevention in Children With HCM. *JACC Cardiovasc Imaging* 2020;13(12):2684-2686.
43. Leung SW, Elayi CS, Charnigo RJ Jr, Syed MA. Clinical significance of right ventricular dysfunction in left ventricular non-compaction cardiomyopathy. *Int J Cardiovasc Imaging*. 2012;28(5):1123-31.

## FIGURE LEGENDS


**Figure 1.** Correlation between RV EF and LV EF



**Figure 2.** LV EDV/BSA comparison between LVNC patients with and without LGE.



**Figure 3.** Bland-Altman plot of left ventricular end-diastolic volume mass indexed to body surface area (LV EDV/BSA). ECHO indicates echocardiography; CMR, cardiovascular resonance imaging; SD, standard deviation.



TABELS

**Table 1.** Baseline characteristics (n = 25)

Sex (% male)	44% (11/25 boys)
Age (years)	11.3 ± 4.0
Height (cm)	144 ± 25
Weight (kg)	39 ± 19
Body mass index (kg/m <sup>2</sup> )	17.5 ± 3.8
Body surface area (m <sup>2</sup> )	1.25 ± 0.41
Heart rate (beats per minute)	73 ± 20

**Table 2.** Echocardiographic and CMR imaging studies

	All patients (n=25)
<b>Echocardiography</b>	
NC in systole, mm, median, IQR	11.0 (9.8, 15.8)
C in systole, mm, median, IQR	4.4 (3.7, 4.8)
NC/C ratio in systole, median, IQR	2.60 (2.22, 3.30)
NC in diastole, mm, mean, SD	13.2±4.5
C in diastole, mm, mean, SD	3.6±1.3
NC/C ratio in diastole, median, IQR	3.40 (2.77, 4.80)
LVED vol., mL, median (IQR)	79 (50, 100)
LVED vol. index, mL/BSA, mean, SD	65±16
LVES vol., mL, mean, SD	34±16
LVES vol. index, mL/BSA, mean, SD	27±8
LVED area, cm <sup>2</sup> , mean, SD	25±8
LVED area z-score, mean, SD	0.74±1.46
LVES area, cm <sup>2</sup> , mean, SD	14±5
LVES area z-score, mean, SD	-1.04±1.76
LVDd, mm, median, IQR	45 (37, 52)
LVDd z-score, mean, SD	1.39±1.68
LVSD, mm, median, IQR	30 (25, 36)
LVSD z-score, median, IQR	1.30 (0.00, 3.15)
LVEF acc. Simpson formula, %, mean, SD	60±6
SF, %, mean, SD	34±5
MAPSE lateral, mm, mean, SD	14±3
MAPSE lateral z-score, mean, SD	-0.60±2.24
LAd, mm, mean, SD	28±4
LAd z-score, mean, SD	0.65±1.38
RVDd, mm, mean, SD	21±5
RVDd z-score, median, IQR	0.25 (-0.10, 0.80)
TAPSE, mm, mean, SD	20±7
TAPSE z-score, mean, SD	-0.29±2.95
RV FAC, %, mean, SD	45±7
LV enlargement (LVDd z-score > 2.0)	10/25 (40%)
LV function impairment (LVEF ≤ 55%)	6/25 (24%)
RV enlargement (RVDd z-score > 2.0)	1/25 (4%)
RV function impairment (FAC ≤ 35%)	1/25 (4%)
LA enlargement (LAd z-score > 2.0)	2/25 (8%)
<b>Cardiovascular magnetic resonance</b>	
LV EDV, mL, mean, SD	107±51
LV EDV/BSA mL/m <sup>2</sup> , mean, SD	84±22
LV EDV, z-score, mean, SD	0.65±1.61
LV ESV, mL, median, IQR	33 (24, 52)
LV ESV/BSA, mL/m <sup>2</sup> , median, IQR	32 (22, 37)
LV ESV, z-score, mean, SD	1.24±1.43
LV SV, mL, mean, SD	66±30
LV SV/BSA, mL/m <sup>2</sup> , mean, SD	52±14
LV SV, z-score, mean, SD	0.70±1.64
LV mass, g, mean SD	68±27
LV mass/BSA, g/m <sup>2</sup> , median, IQR	50 (45, 58)
LV mass, z-score, median, IQR	-0.18 (-0.71, 0.47)
LV EF, %, mean, SD	62±8
LV CI, L/m <sup>2</sup> , mean, SD	3.62±0.76
RV EDV, mL, mean, SD	111±51

RV EDV/BSA, mL/m <sup>2</sup> , mean, SD	87±21
RV EDV, z-score, mean, SD	0.44±1.52
RV ESV, mL, mean, SD	46±25
RV ESV, mL/m <sup>2</sup> , mean, SD	36±12
RV ESV, z-score, mean, SD	0.57±1.67
RV SV, mL, mean, SD	65±30
RV SV/BSA, mL/m <sup>2</sup> , mean, SD	51±14
RV SV, z-score, mean, SD	0.18±1.46
RV EF, %, mean, SD	59±9
RV EF, z-score, mean, SD	-0.87±2.18
RV CI, L/m <sup>2</sup> , median, IQR	3.45 (3.20, 3.75)
LV NC, mm, median, IQR	12.5 (11.8, 13.7)
LV C, mm, mean, SD	4.0±0.7
LV NC/C, median, IQR	3.27 (2.56, 3.76)
LA max volume, mL, mean, SD	43±19
LA max volume/BSA, mL/m <sup>2</sup> , median, IQR	30 (27, 43)
LV enlargement (LV EDV z-score >1.65)	5/25 (20%)
LV function impairment (LVEF <55%)	6/25 (24%)
RV enlargement (RV EDV z-score >1.65)	4/25 (16%)
RV function impairment (RVEF <55%)	7/25 (28%)
LA enlargement (LA >97. percentile)	5/25 (20%)

NC - noncompaction of ventricular myocardium, C - compaction of ventricular myocardium, LVED vol. - left ventricular (LV) end-diastolic volume, LVES vol. - left ventricular end-systolic volume, LVDd - left ventricular diastolic diameter, LVSd - left ventricular systolic diameter, LVEF - left ventricular ejection fraction, SF - fractional shortening, MAPSE - mitral annulus peak systolic excursion, LAd - left atrial diameter, RVDd – right ventricular diastolic diameter, TAPSE - tricuspid annular plane systolic excursion, RV FAC - right ventricular fractional area change.

**Table 3.** CMR LV NC/C ratio correlations with echocardiographic indices of the extent of LV trabeculations

	<b>ECHO NC/C in systole</b>	<b>ECHO NC/C in diastole</b>
<b>CMR LV NC/C in diastole</b>	r=0.41, p=0.044	r=0.34, p=0.093

**Table 4.** Echocardiography versus CMR

	Sensitivity	Specificity	PPV	NPV	Accuracy
LV enlargement	80 (28-99)	65 (41-85)	36 (21-55)	93 (69-99)	68 (47-85)
LV function impairment	83 (36-100)	95 (74-100)	83 (42-97)	95 (75-99)	92 (74-99)
RV enlargement	25 (1-81)	95 (76-100)	50 (7-93)	87 (79-92)	84 (64-95)
RV function impairment	14 (0-58)	100 (81-100)	100	75 (69-80)	76 (55-91)
LA enlargement	40 (5-85)	100 (83-100)	100	87 (77-93)	88 (69-97)